- Pressemitteilung BoxID 332168
4SC Discovery, Crelux and Ribological launch collaboration for the discovery and optimisation of new anti-cancer drugs
4SC Discovery and Crelux GmbH, its strategic partner for services in the field of biopharmaceutical early-stage research, have been commissioned by Ribological to implement a hit finding programme to identify and optimise potential new small molecule compounds that are expected to have a synergistic effect with the RNA molecules used by Ribological in cancer immunotherapy. Ribological intends to carry out preclinical testing of the compounds and, if successful, develop these further in clinical trials in combination with its RNA-based drugs.
In detail, 4SC Discovery is using its patented IT-aided in silico screening process to perform calculations of the properties of several million substances with the goal of identifying the best possible drug candidates. This is intended to accelerate the development process for early-stage compound research and achieve greater cost efficiency than conventional approaches. Crelux, 4SC Discovery's research partner that specialises in research services in the field of proteins, especially protein production and crystallisation, is performing the associated molecular-biological tests for optimising the compounds in INTRACT-MST assays.
The partnership will generate revenue that could reach the low six-figure euro range for each 4SC Discovery and Crelux.
Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'We are delighted to have secured Ribological as a cooperation partner for our drug discovery activities - a company with a strong research track record and a highly innovative approach in cancer medicine. This is also the first major joint project that we have launched as part of our new strategic i2c (idea to candidate) cooperation with our partner Crelux. As service providers and cooperation partners for biotech and pharma companies, 4SC Discovery and Crelux together can cover both the entire value chain from the idea for a product to the preclinical drug development candidate and also supplement it as needed.'
Prof. Dr. Ugur Sahin, Managing Director of Ribological GmbH, comments: 'In 4SC Discovery GmbH we have won an expert and, simultaneously, an exceedingly pleasant cooperation partner for small molecule compound screening. We expect this to be a high-level synergistic collaboration.'
About the i2c drug discovery platform of 4SC Discovery and Crelux
The integrated drug discovery platform i2c (idea to candidate) of 4SC Discovery and Crelux offers a seamless process from early concept through to a preclinical development candidate ready to advance into formal animal model testing and thereafter into clinical trials. The i2c client groups are pharmaceutical companies looking to outsource part of their early discovery projects and also small and mid-size biotech companies lacking the relevant infrastructure. Besides the standard fee-for-service offerings, i2c also includes research collaborations based on risk sharing models including milestones and royalties. Collaborations are provided as tailor made solutions for smaller sized companies and interested pharmaceutical partners.
About Ribological GmbH
Ribological, based in Mainz, Germany, is a subsidiary of BioNTech AG. Ribological develops pharmacologically optimised, RNA-based drugs for targeted immunotherapy for cancer. The Group parent, BioNTech, is a spin-off from Johannes Gutenberg University, Mainz. Together with its subsidiaries, the company researches and develops molecular diagnostics and targeted immunotherapies for personalised clinical application.
About 4SC Discovery GmbH
4SC Discovery GmbH is a wholly-owned subsidiary of 4SC AG that offers technologies and tailored research services covering drug discovery and chemical optimisation through to a preclinical development candidate. The company focuses its services on offering customers in the pharmaceutical, biotech and chemical industries the cost and time-to-market benefits that result from a drug discovery and optimisation process based on a powerful, computer-aided, screening and discovery platform. In addition, 4SC Discovery also applies its comprehensive pharmacological expertise to investigating new compounds in the areas of cancer and autoimmune disease - a measure also intended to further enhance the clinical development pipeline for the 4SC Group. 4SC Discovery aims to engage in partnerships with pharmaceutical and biotech companies to accelerate the development of its research programmes and further advance their commercialisation.
About CRELUX GmbH
CRELUX (www.crelux.com) specializes in tailor made protein and protein crystallography drug discovery services. The company is a professional and dedicated service provider for the global pharma and biotech industry. CRELUX is privately owned with no venture capital or other external investment and is therefore fully independent of external shareholders. The company is solely committed to long-term development and growth with all profit being re-invested into the business. CRELUX is a client focused provider with a portfolio of premium drug discovery services based on our top level protein expertise. In our PRIME PROTEIN programs we are advancing innovations in protein expression to promote the availability of high quality proteins for use in assays, diagnostics and crystallization. Our XPRESS portfolio of readily available crystallographic targets grants turn-around times within a few weeks. Our XPERT crystallography services from concept to high resolution complex structure are provided under individual agreements following our customer's needs. In addition we are offering compound and fragment screening based on our unique screening technology INTRACT. Finally, our i2c (idea to candidate) service includes target to hit and concept to early development candidate fee-for-service projects.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
The Group managed by 4SC AG discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. At the end of March 2012, 4SC Group had 90 employees. The company was founded in 1997. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Diese Pressemitteilungen könnten Sie auch interessieren
Die milden Temperaturen der letzten Wochen bescheren circa 15 Millionen Allergikern in Deutschland einen frühen Pollenalarm. Die Haselsträucher...
Im Lauf des Jahres 2017 hat das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) seine 200. Dossierbewertung abgeschlossen:...
Die Grippewelle schwappt aktuell über Deutschland, hat die StädteRegion Aachen bislang aber noch nicht voll erwischt. Den einzigen Schutz vor...